Solid Tumors

Phase 1 Study of Single Agent ONX 0801
Currently enrolling
Study Design: Non-randomized, open-label, dose finding trial
Patients: Patients with solid tumors, including lymphomas, who have failed standard therapy or for which no standard curative therapy exists
Purpose: To evaluate the safety and tolerability including dose limiting toxicity;and maximum tolerated dose, as we as to determine the pharmacokinetics of ONX 0801
Location: Select centers in the United Kingdom

Stock Quote (update every 15 minutes): As of 4:00pm - 5/20/2011

  • Symbol
    ONXX
  • Last
    43.71 +0.22
  • Open
    43.46
  • High
    43.81
  • Low
    42.49
  • Volume
    1139204